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Abstract 
Multiple Sclerosis (MS) is a common autoimmune disease whereby myelin is destroyed 
by the immune system. The disease is triggered by the stimulation of encephalitogenic 
T-cells via the formation of a trimolecular complex between the Human Leukocyte 
Antigen (HLA), an immunodominant epitope of myelin proteins and T-cell Receptor 
(TCR). Myelin Oligodendrocyte Glycoprotein (MOG) is located on the external surface 
of myelin and has been implicated in MS induction. The immunodominant 35-55 
epitope of MOG is widely used for in vivo biological evaluation and immunological 
studies that are related with chronic Experimental Autoimmune Encephalomyelitis 
(EAE, animal model of MS), inflammatory diseases and MS. In this report, Molecular 
Dynamics (MD) simulations were used to explore the interactions of the MOG35-55 at 
the receptor level. A detailed mapping of the developed interactions during the creation 
of the trimolecular complex is reported. This is the first attempt to gain an 
understanding of the molecular recognition of the MOG35-55 epitope by the HLA and 
TCR receptors. During the formation of the trimolecular complex, the residues Arg41 
and Arg46 of MOG35-55 have been confirmed to serve as TCR anchors while Tyr40 
interacts with HLA. The present structural findings indicate that the Arg at positions 41 
and 46 is a key residue for the stimulation of the encephalitogenic T-cells.  
 
Keywords: Bioactive conformation; Molecular Dynamics; Multiple Sclerosis (MS); 
Myelin Oligodendrocyte Glycoprotein (MOG); Human Leukocyte Antigen (HLA); T-
cell Receptor (TCR) 
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1. Introduction 
  
 Multiple Sclerosis (MS) is the most common autoimmune disease of the Central 
Nervous System (CNS) in which a coordinated attack of the immune system against 
myelin takes place. 1, 2 Myelin Basic Protein (MBP), Proteolipid Protein (PLP), Myelin 
Oligodendrocyte Glycoprotein (MOG) and Myelin-Associated Glycoprotein (MAG) 
are the main myelin proteins in the CNS and they have been recognized as putative 
auto-antigens for MS.3 MS onset is triggered by the activation of the encephalitogenic 
T-cells through the formation of a trimolecular complex between the T-cell receptor 
(TCR), the peptide (antigen) -with identical residue sequence to a fragment of a protein 
of the myelin sheath (molecular mimicry theory)4, 5- and the Major Histocompatibility 
Complex (MHC) or Human Leukocyte Antigen (HLA). The ability of the peptide-HLA 
complex to activate T-cells is correlated with the strength of its binding affinity with 
TCR.6-8 Conversely, stimulation or not of T-cells that are responsible for MS follows.9-
13
 The HLA class II receptors are dimers comprised of two different polypeptide 
chains (α and β).14, 15 In this class of macromolecules the polypeptide chains are joined 
together, creating a single receptor for the antigens to bind to. Subsequently, the newly 
formed complex is recognized by the receptors on the surface of T-cells. The formation 
of the trimolecular complex leads to the activation of the T-cells through a cascade of 
biochemical changes and the induction of the immune response to the antigen. The TCR 
is also composed of two different polypeptide chains. The two chains comprising the 
TCR (α and β), include variable domains called Complementarity Determining Regions 
(CDRs). These domains are implicated in the recognition process between the TCR and 
the HLA-antigen complex.16 The diversity of the CDRs plays a crucial role in the 
recognition of the different antigens as they are presented by the HLA receptors. The 
CDRs comprising the TCR chains are very effective at screening the various antigens 
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presented to the T-cells.9, 17 It has been estimated by in vivo experiments that the TCR 
unique structures in humans are over >2.5x107.17, 18 Despite the diverse numbers and 
the rigorous selection process of T-cells in the thymus,19, 20 there are cases where the 
selection process fails to single out T-cells reacting to self-antigens.21 Thus, the failure 
in the thymic selection leads to self-reactive T-cells and induction of autoimmune 
disorders such as MS.22, 23  
 The myelin sheath consists of multiple proteins; MBP and PLP are two of the 
major component of the myelin sheath, while MOG and Myelin-associated 
Glycoprotein (MAG) are less abundant.24, 25 The total myelin proteins consist of only 
0.05%-0.1% of MOG;24, 25 however MOG or MOG epitopes activate T-cell immune 
responses in Experimental Autoimmune Encephalomyelitis (EAE, animal model of 
MS) and have also been associated with MS induction.26, 27 There have been extensive 
studies of different fragments of MOG as autoimmune triggers.28-32 The MOG epitopes 
1-22, 61-80, 92-106 have been highlighted as target antigens and the 35-55 epitope has 
been found to induce highly specific antibodies reacting similar to the entire MOG 
protein.33, 34 Moreover, T-cell responses to MOG epitopes have been measured through 
biological assays in MS patients.29, 30 
  The MOG35-55 epitope (M35EVGWYRS42PFSRVVHLYRNGK55), based on the 
mouse/rat MOG peptide sequence, is shown as strongly immunogenic in mice leading 
to the development of chronic EAE.27, 35 Our group has previously rationally designed 
and synthesized linear and cyclic peptide analogues of human MOG35-55 
immunodominant epitope (hMOG35-55) with crucial TCR substitutions.26 These altered 
peptides have proved to inhibit the clinical manifestation of symptoms of chronic EAE 
in mice.26 The substitutions of Arg at positions 41 and 46 by Ala, result in peptide 
analogues that reduce the severity of MOG-induced EAE clinical symptoms in 
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C57BL/6 mice when co-administered with mouse/rat MOG35-55 peptide at the time of 
immunization.26 The observed results justify the importance of Arg at positions 41, 46 
for EAE induction.26  
 To the best of our knowledge no conformational study of hMOG35-55 epitope in 
complex with TCR and HLA has been reported. Hence, this is the first attempt to 
provide a deeper understanding of the structural requirements in the trimolecular 
complex with hMOG35-55 epitope. A detailed analysis of interactions between hMOG35-
55 and the respective receptors (HLA and TCR) could provide valuable information for 
rational design of altered peptide ligands (APLs) and non-peptide mimetics with 
inhibitory activity. Herein, the structural properties of hMOG35-55 in three different 
environments were investigated, through the use of molecular dynamics simulations: i) 
we looked at the adopted conformations by the peptide in aqueous solution, ii) we 
carried out MD simulation studies using hMOG35-55 in combination with HLA DR2 
(DRA, DRB1*1501) receptor and iii) the created trimolecular complex between 
hMOG35-55, HLA DR2 and TCR was explored. The investigation of the interactions 
between hMOG35-55 and the receptors in the trimolecular complex is expected to 
provide important information on the binding patterns of the hMOG epitope, which can 
assist researchers in the rational design of novel molecules, focusing on the inhibition 
of the stimulated encephalitogenic T-cells that are responsible for EAE and MS 
induction.  
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2. Methods 
 The high resolution crystal structure of HLA DR2 (DRA, DRB1*1501) in 
complex with the MBP83-96 antigen (E83NPVVHFFKNIVTP96) and TCR was used for 
the MD simulations (PDB code: 1ymm).36 The hMOG35-55 epitope 
(M35EVGWYRP42PFSRVVHLYRNGK55), based on the human sequence, used for the 
simulation studies was constructed using PyMOL.37 During this process the amino 
acids (L configuration), comprising the peptide, were placed in sequential order with 
no initial secondary structure assignment (unfolded conformation). The different 
systems were subjected to all-atom unrestrained MD simulations in explicit solvent 
using AMBER14.38 
 
2.1 Molecular Dynamics (MD) simulation of hMOG35-55 
 For the construction of the hMOG35-55 peptide parameters, the AMBER force 
field ff14SB39 has been used. The TIP3P water model40 was utilized for the solvation 
of the system and the total charge was neutralized by the addition of three Cl- ions. 
Truncated octahedral periodic boundary conditions have been applied to the system 
with a cutoff distance of 10 Å. The next step involved the minimization, followed by 
the heating of the system, under constant volume, to 300K for 100ps using the Langevin 
dynamics temperature scaling.41 This was followed by equilibration for another 100 ps 
under constant pressure. Both heating and pressure equilibration were performed using 
a 10 kcal mol-1 Å-2 restraint on the solute. The equilibration step under constant pressure 
was prolonged for a further 200 ps, after removing all restraints. The MD production 
run was performed under constant pressure and temperature conditions (NPT ensemble) 
for 100 ns. The temperature was kept constant with the use of the Langevin thermostat 
(using a collision frequency of 2 ps-1). All bonds involving hydrogen atoms were kept 
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to their equilibrium distance with the SHAKE algorithm (allowing for a 2 fs time step 
to be used).42 The long range electrostatic interactions were calculated with the Particle 
Mesh Ewald (PME) method.43 
 
2.2 Molecular Dynamics (MD) simulation of the hMOG35-55 complexed with the HLA 
DR2 receptor  
 The positioning of the hMOG35-55 epitope inside the HLA DR2 receptor was 
performed manually using PyMOL.37 The minimized structure (Section 2.1) of the 
linear hMOG35-55 epitope was superimposed with the crystal structure of the MBP83-96 
epitope (PDB code: 1ymm).36 The orientation of hMOG35-55 resembles the positioning 
of the MBP83-96 epitope inside the binding pocket of HLA DR2.36, 44 The residues Tyr40, 
Pro43, Ser45 and Val48 of hMOG were placed in the respective pockets (P1, P4, P6 and 
P9 for HLA DR2), as reported in the literature.36, 44, 45 In the next step, the residues 
comprising the TCR were removed along with all crystallographic water molecules. 
The missing hydrogens were added using the tLeap module in AMBER14. 
 As with the MD simulation of hMOG35-55 in water, the parameters for the receptor 
were constructed using the AMBER force field ff14SB.39 The total charge of the system 
was neutralized with the addition of fourteen Na+ ions. The TIP3P water model40 was 
used in the solvation of the system and truncated octahedral periodic boundary 
conditions were applied to the system with a cutoff distances of 10 Å. The system was 
minimized over 5000 steps, followed by the gentle heating to 300K over 100 ps, using 
the Langevin dynamics temperature scaling (time step 2 fs). The system was further 
equilibrated under constant pressure for 100 ps. As mentioned in section 2.1, both the 
heating and equilibration steps were performed using a 10 kcal mol-1 Å-2 restraint on 
the solute. A 200 ps equilibration step, under constant pressure, was performed 
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following the removal of the restraint on the solute. Finally, an MD production run for 
40 ns was performed using the NPT ensemble. 
 
2.3 Molecular Dynamics (MD) simulation of TCR-hMOG35-55-HLA DR2 complex  
 For the MD simulation of the hMOG35-55 epitope in complex with both TCR and 
HLA the construction of the system followed the same steps described in section 2.2. 
The minimized conformation of the linear hMOG35-55 epitope (Section 2.1) was 
superimposed with the crystal structure of HLA DR2/MBP83-96/TCR). Thus, the TCR 
from the crystal structure was positioned over the hMOG35-55-HLA DR2 complex. 
Subsequently, the MBP83-96 peptide was removed from the crystal structure along with 
the water molecules. The preparation of the system and the MD simulation followed 
the steps mentioned in section 2.2. A total of thirteen Na+ ions were used to neutralize 
the system and the solvation of the complex in explicit solvent was done using the 
TIP3P water model.40
 
 A 40 ns MD production run in the created trimolecular complex was performed 
using AMBER14.38 Studies in similar biological systems show that the simulation time 
reported here is adequate for the conformational analysis of the bound epitope.46-50 The 
parameters for the proteins and the peptide were constructed using the AMBER ff14SB 
force field.39 The next step involved the minimization of the system followed by the 
heating of the complex to 300 K for 100 ps. Constant pressure equilibration was 
performed for a total of 300 ps. During the first 100 ps, a 10 kcal mol-1 Å-2 restraint 
constant was imposed on the solute, which was then removed for the rest of the 
equilibration run. The MD production run was attained under isothermal and isobaric 
conditions and the temperature was kept constant with the use of the Langevin 
thermostat. The bonds involving hydrogen atoms were kept to their equilibrium 
9 
 
distance with the SHAKE algorithm.42 The Particle Mesh Ewald (PME) method43 was 
implemented for the calculation of the long range electrostatic interactions. Following, 
the above procedure, we also performed two MD simulations with mutated forms of 
hMOG35-55, namely: hMOG35-55(Ala41) and hMOG35-55(Ala41,46). In these variants, the 
Arg was replaced by Ala in position 41 and in positions 41/46, respectively.  
 
2.4 Trajectory and Clustering analysis 
 The analysis (Rms deviations, atomic fluctuations and 
clustering calculations) of all the AMBER MD trajectories, was carried out using the 
cpptraj module51 of the AMBER14 molecular package. The analysis of the hydrogen 
bond (HB) interactions was based on geometrical criteria, the limitations imposed were 
a 3.5 Å cutoff for donor-acceptor distance and a donor-hydrogen-acceptor angle cutoff 
of 120°. For the clustering analysis of the various MD trajectories, the hierarchical 
method52 was used in the grouping process, with the Rms being the distance metric 
(cutoff 2.0 Å). The representative conformations presented in the paper are snapshots 
taken from the reference (centroid) simulation frames, used during the clustering 
analysis by the cpptraj module. 
 
3. Results 
3.1 Conformational characteristics of hMOG35-55 epitope 
 The analysis of the MD trajectory for the hMOG35-55 in solution revealed that 
hMOG35-55 does not retain an extended form. The different conformations adopted 
throughout the 100 ns trajectory, showed that the dominant form of the peptide presents 
two bends (Figure 1a). The particular conformation is displayed on approximately 40% 
of the simulation time. The bend conformation of the peptide may be partly attributed 
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to its hydrophobic content (Figure 1b, thicker ribbon). The hydrophobic residues may 
force the polypeptide chain to seek conformations that decrease their exposure to the 
solvent. As expected, the small length does not allow the peptide to adopt a more stable 
secondary structure like α-helix or β-sheet. Instead hMOG35-55 remains in a largely 
unfolded state in aqueous solution, in accordance with experimental observations.53, 54 
 The adoption of a bend conformation by the peptide is further supported by the 
analysis of the secondary structures of the residues during the MD simulation (Figure 
S1, in Supporting Information). It is evident that the secondary structure of the peptide 
does not present a stable conformational profile throughout the MD simulation (Figure 
S1). Though, it displays certain helical features, such as bends and turns (Figure S1, red 
and brown colours, respectively). These observations are in close agreement with those 
reported by Albouz-Abo et. al (1997).53 In the particular paper, Circular Dichroism 
(CD) data is reported in both the rat and human forms of MOG35-55. The CD 
experiments show evidence of helical conformations adopted mainly by the rat 
sequence and to a lesser extent by the human form of MOG in increased concentrations 
of trifluroethanol.53 In our theoretical model (Figure 1), the hMOG35-55 peptide presents 
a semi-closed conformation (random coil) as also reported by the study of Albouz-Abo 
et. al. in aqueous solution. The proposed conformation also presents, common features 
with the closed conformation reported for the rat/mouse MOG35-55 peptide by 
Ntountaniotis, et. al (2016, doi.org/10.1080/07391102.2016.1188418)54 in both DMSO 
and aqueous solutions. The dominant form of hMOG35-55 (Figure 1a, Figure S2), 
displays two bends in the polypeptide backbone. The first bend is observed between 
residues Trp39, Tyr40 and Arg41 (Figure 1a and Figure S1 red colour) and the second in 
the area defined by residues Val48 and Arg52 (Figure S1, red colour). The particular 
conformation of the peptide is defined by the presence of extensive hydrogen bonds 
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between the different amino acids. The most important interactions are those between 
residues Glu36-Arg41 and Glu36-Phe44 (Figure 1a, dark green lines). The hydrogen bond 
between the backbone carbonyl -O of Glu36 and the backbone -NH of Phe44 causes the 
peptide to form a loop, which is further stabilized by the interactions between the side 
chains of Glu36 and Arg41 (Figure 1a). This loop appears almost throughout the 
simulation time as shown by the clustering analysis. Besides the above mentioned 
dominant form of hMOG35-55 (Figure 1c, black), there are two more representative 
conformations (Figure 1c, blue and green) in the MD simulation. Although both of these 
conformations retain the loop between residues 35-44, the second bend observed in the 
dominant form does not appear in these structures. The hydrogen bond between Val48 
and Arg52 (Figure 1a) is absent in these conformations leading to the loss of the second 
bend in the structure of the peptide. 
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Figure 1: (a) The dominant conformation of the hMOG35-55 peptide in water, showing 
the hydrogen bonds (as green lines) between the residues, (b) schematic representation 
of the hydrophobic content of the hMOG35-55 peptide. The hydrophobicity of each 
residue is represented by the thickness of the ribbon and (c) superimposition of the three 
representative conformations of the hMOG35-55 peptide in the MD simulation. 
 
3.2 Conformational analysis of hMOG35-55-HLA DR2 receptor complex  
 A visual inspection of all the conformations during the MD simulation was 
carried out and the amino acids of the hMOG35-55 with side chains that were oriented 
into the HLA DR2 main pockets were recorded (Figure S3). The conformational 
analysis of the hMOG35-55-HLA DR2 complex showed that the peptide occupies 
pockets 1, 4, 6 and 9 of the receptor (Figure S3). These four pockets are the same areas 
occupied by the MBP83-96 epitope (Figure 2). The clustering analysis in the MD 
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production run of hMOG35-55-HLA DR2 complex revealed that the dominant 
conformation of the peptide is the one depicted in Figures 2 and S3. In fact, the 
particular conformation is found to be present for approximately 70% of the simulation 
time. This observation may suggest that the hMOG35-55 epitope favours a particular 
conformation when bound to HLA DR2 and retains this structure during most of the 
simulation time. The Rms deviations recorded during the MD simulation, show that 
both hMOG35-55 and the HLA receptor retain a stable configuration throughout the MD 
simulation (Figure 3a and 3b, blue), with respect to their initial configuration. 
  A more detailed examination showed that in pockets 1, 6 and 9, the residues 
interacting with the HLA DR2 receptor are similar in nature to those of the MBP83-96 
epitope occupying the same space in the receptor (Figure 3). For instance, Tyr40 
(hMOG35-55) and Val87 (MBP83-96) have both hydrophobic side chains and are oriented 
towards a buried area of the HLA receptor in pocket P1 (Figure 2). The specific area of 
the receptor is rich in hydrophobic residues, such as Phe24, Phe26, Ile31, Phe54 and Val85 
(Figure 2, red surface colour). Moreover, the bulkier side chain of Tyr40 (hMOG35-55) 
is buried deeper in the particular pocket of HLA and may enhance the hydrophobic 
interactions between the epitope and the receptor, compared to MBP83-96. A similar 
trend is observed in the P6 pocket of HLA with the presence of Ser45 (hMOG35-55) and 
Asn92 (MBP83-96), which both present polar side chains. The -OH group from Ser45 
(hMOG35-55) interacts with neighbouring residues such as Glu31, Asn62 and Asp66 of the 
HLA. Likewise, the amide side chain of Asn92 (MBP83-96) interacts with the same amino 
acids of the receptor in the P6 pocket. Finally, in P9 pocket both hMOG35-55 and MBP83-
96 have in the same position (48 and 94, respectively) a Val residue, surrounded by 
amino acids Val65 and Ala68 of the receptor (Figure 2). The only difference between the 
two epitopes is focused in the P4 pocket of HLA DR2. In hMOG35-55 there is Pro43 in 
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the P4 pocket of HLA while MBP83-96 has a hydrophobic residue (Phe90) at the same 
position. The P4 pocket of the receptor includes residues with polar side chains, thus 
the smaller and restricted side chain of Pro may induce conformational changes in the 
residues surrounding Pro43 that may lead to a better positioning inside the P4 pocket of 
the HLA receptor.55  
 
 
 
 
 
 
 
 
 
Figure 2: The binding cavity, depicted as surface, of HLA DR2 shows the pockets P1, 
P4, P6 and P9 in the dominant representative conformation of the HLA DR2 -hMOG35-
55 complex. The hMOG35-55 (green) epitope is superimposed with the crystal structure 
of MBP83-96 (purple) taken from the crystal structure 1ymm. The peptides’ backbone is 
represented as ribbon and the side chains of the residues are outlined as sticks. The 
surface of the receptor is coloured according to the Kyte-Doolittle hydrophobic index. 
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Figure 3: RMS deviations of the backbone Cα atoms in all MD simulation runs in 
comparison to their starting configurations for (a) hMOG35-55, (b) HLA DR2 receptor 
and (c) TCR. 
 
3.2.1 Hydrogen bond interactions in hMOG35-55-HLA DR2 receptor complex 
  A detailed analysis of the hydrogen bonds (HBs), between the amino acids of 
hMOG35-55 and the HLA DR2 receptor, was carried out and the results are presented in 
Table 1. An important feature observed in the analysis of the MD simulation is the lack 
of water mediated hydrogen bonds between the peptide and the receptor. The binding 
cavity includes residues with bulky side chains such as Asn69, Gln71, Arg76, His81 and 
Asn82 in HLA (Table 1), that may prevent water molecules to move between receptor 
and epitope residues and consequently interact with either.  
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Table 1: Residues in HLA DR2 receptor that are involved in HBs with those of the 
hMOG35-55 epitope, as recorded in all the MD simulations. 
Peptide 
sequence a 
MD simulationsb 
hMOG35-55-HLAc 
TCR-hMOG35-55-HLA complexes 
hMOG35-55 hMOG35-55 (Ala41) hMOG35-55 (Ala41,46) 
Met35 – – – Glu87 
Glu36 – – – Arg80,Glu87 
Val37 Arg80 – – – 
Trp39 Arg80 Thr77,Arg80 Arg80 – 
Tyr40 His81 His81,Asn82 - Glu55 
Arg41 Gln70 Glu55 His81 Tyr78 
Pro43 Asn62 – – – 
Phe44 – Gln70 Gln70 Gln70 
Ser45 Asp66,Asn62 – Asn62 Asn62,Arg13 
Arg46 – Asp66 Gln64 – 
Val47 – - – Asn69 
Val48 – - Gln64 – 
His49 – Ala61 Asp66 Asn69 
Leu50 – – – Tyr60 
Tyr51 Ala64 – Pro56 – 
Arg52 Lys67 – – Asp57 
Lys55 Gln18 – – – 
a
 Only the residues involved in hydrogen bonds are presented here 
b
 For detailed information on hydrogen bonds see Table S1 in Supporting Information. 
c
 Only HBs with occurrence of more than 20% of the simulation time are presented here. 
 
 
 As observed in Table 1, hMOG35-55 creates an extensive hydrogen bond network 
with the HLA receptor. In pocket P1 of the HLA DR2, Tyr40 interacts with His81 from 
HLA anchoring the peptide in such a way to facilitate the interactions of its 
neighbouring residues (namely Trp39, Arg41 and Pro43). In fact Trp39 is involved in 
interactions with Arg80 in P1 pocket as well as Ser53 which is located in proximity to 
P1 pocket. Moreover, Arg41 due to its polar side chain, creates hydrogen bonds with 
three different amino acids of HLA (Gln70, Asp76 and Thr77, Table 1) that are located in 
the P4 pocket and its vicinity, although such interactions are not appearing throughout 
the simulation time. This may be explained by the fact that the side chain of Arg41 is 
positioned towards the external area of the HLA receptor in a solvent exposed 
environment and may lead to extensive interactions with the TCR. Finally, Pro43 is 
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interacting with Asn62, located in the area between pockets P4 and P6 of the HLA, with 
the particular interaction being present throughout most of the simulation time. The 
particular HB interaction may enhance the HBs created between Arg41 and the receptor. 
Another residue of hMOG35-55, implicated in HB formation is Ser45, which forms 
extensive HBs with Asn62 and Asp66 in P6 of the HLA receptor. Even residues such as 
Arg52 and Lys55 of the peptide, despite being positioned outside the binding areas P1, 
P4, P6 and P9 are interacting with residues of the HLA (Lys67 and Gln18, Gly20, 
respectively). These extensive interactions with the receptor may increase the binding 
affinity of the hMOG35-55.  
 As mentioned in section 3.1, hMOG35-55 adopts a bend conformation due to the 
presence of HB formed between residues such as Glu36 and Phe44 (Figure 1). When 
bound to the HLA DR2 receptor, this conformational feature is not retained (Figure 2) 
which is expected, since the interactions between the epitope and the residues of the 
receptor may lead to a conformational rearrangement of the epitope in order to enhance 
its binding. The bend aspect of the hMOG35-55 peptide is an essential feature, because 
it allows the epitope to reach inside the receptor. Thus, residues such as Tyr40 and Pro43 
may interact with residues in different pockets (P1 and P4, respectively) and create a 
more extensive HB network with the HLA DR2 molecule. 
 
3.3 Conformational analysis of the trimolecular complex (TCR-hMOG35-55-HLA 
DR2) 
 As discussed in the Methods section (Section 2.3), the positioning of the hMOG35-
55 epitope in the trimolecular complex was carried out via the superimposition of the 
epitope with the crystal structure of the MBP83-96 peptide. Thus, the amino acids of 
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hMOG35-55 and MBP83-96 occupy similar pockets inside the TCR and HLA DR2 
receptors. Furthermore, as reported in Section 3.2, hMOG35-55 retains its initial 
positioning in the HLA DR2 pockets 1, 4, 6 and 9 throughout the simulation. In that 
respect, residues such as Arg41 and mainly Arg46 of the peptide are facing towards the 
solvent when bound to HLA allowing the peptide to create enhanced interactions with 
the TCR during the antigen recognition process. This can be partially explained by the 
relative stable conformations observed in the trimolecular complex in the MD 
simulation. The Rms values for hMOG35-55 and the two receptors (HLA and TCR) after 
the first 5 ns of the simulation, remain relatively stable throughout the MD run (Figure 
3, green). This observation is in accordance with the conformational changes in the 
hMOG35-55-HLA DR2 complex. The conformational changes of the HLA receptor are 
similar in the trimolecular and hMOG35-55-HLA DR2 complexes (Figure 3b, green and 
blue), as well as in the hMOG35-55 epitope (Figure 3a, green and blue). The difference, 
compared to the starting configuration, for the peptide in the two systems can be 
attributed to the interactions arising between hMOG35-55 and both receptors in the case 
of the trimolecular complex (Figure 3a). 
 
3.3.1 Clustering analysis of the trimolecular complex (TCR-hMOG35-55-HLA DR2) 
 The clustering analysis showed that there are four representative clusters 
throughout the simulation (Figure 4a). The different conformations of hMOG35-55 in 
their majority are exemplified by the bend conformation (Figure 4a, red). The particular 
conformation is appearing at 67% of the frames in our simulation. The other three 
clusters are present for a small percent of the simulation each, and are mostly appearing 
during the first 5 ns, suggesting that the peptide prefers the bend conformation that is 
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appearing on Pro42,43, in the presence of TCR and HLA. The aforementioned 
conformation may play a role in the orientation of hMOG35-55 in the binding pocket of 
TCR.  One such example is the positioning of Arg41 inside pockets P2 and P3 of TCR 
(Figure 4b) that may lead to enhanced interactions with the TCR. Moreover, it may 
orient other residues of hMOG35-55 in such a way so as to be correctly placed in the 
binding cavity of TCR. The orientation of the peptide in the TCR does not affect only 
the interactions between hMOG35-55 and TCR, but also the interactions with the HLA 
receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: (a) Representative structures of the 4 clusters generated from the MD 
simulation of the trimolecular complex (TCR-hMOG35-55-HLA DR2). In red is the 
representative conformation of the most dominant cluster (67%) during the simulation. 
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(b) The position of Arg41 (dominant cluster) in the TCR pockets P2, P3 and the 
proximity to residues 101-105 allow the Arg to form extensive HBs, as reported in 
Table 2. 
 
3.3.2 Hydrogen bond interactions in the trimolecular complex (TCR–hMOG35-55–HLA 
DR2) 
 It was observed in the hMOG35-55-HLA DR2 complex that Tyr40 (hMOG35-55) is 
positioned similarly to Val89 (MBP83-96) and also creates HBs with the same amino acid 
-namely His81- of HLA in the trimolecular complex (Table 1). Similarly, in the 
trimolecular complex, Trp39 (hMOG35-55) participates in HB formation with residues 
(Arg80, Thr77) inside pocket P1 of the HLA DR2 receptor (Table 1). The interactions of 
hMOG35-55 with the TCR are reported in Table 2. In general, hMOG35-55 retains similar 
HB interactions when bound either to HLA or TCR and HLA together (Table 1) and 
the most important residues of the epitope are the two Arg in positions 41 and 46  
Table 2: TCR residues that interact with residues of the hMOG35-55 epitope for the 
formation of respective HBs, as recorded in all the MD simulations.  
Peptide sequencea 
TCR-hMOG35-55-HLA MD simulationsb 
hMOG35-55 hMOG35-55(Ala41) hMOG35-55(Ala41,46) 
Met35 Thr94 – – 
Glu36 Ser28 – Ser28 
Gly38 Ser95 Ser95 Ser95 
Trp39 – – Ala103,Gly96 
Tyr40 Tyr98 Tyr98 – 
Arg41 Gly102,Asn104 – – 
Ser45 – Thr100 – 
Arg46 Asp98,Thr100, Glu106 Asp98,Thr100, Gly106 – 
Arg52 Ser25 – – 
Asn53 Gln29,Thr75 – – 
Gly54 – – – 
Lys55 Arg24 – – 
a
 Only the residues involved in hydrogen bonds are presented here 
b
 For detailed information on hydrogen bonds see Table S2 in Supporting Information. 
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 It has been theorised that Pro42 in hMOG35-55 plays a crucial role in the binding 
of the peptide to the TCR. The rigid region around Pro42-Pro43 (Figure 4a) seems to 
create a bend in the peptide. This structural feature allows the peptide to bend in a way 
that assists the interactions between Arg41 of the peptide and the TCR. In fact, Arg41 
seems to reach easier into the pocket P3 of the TCR, in the presence of this bend. This 
conformational change may be the reason for the enhanced HB interactions of Arg41 
with residues Gly102 and Asn104 in TCR. Also, it may lead to the HB formation between 
Arg46 and residues Asp98, Thr100 and Glu106 of the TCR. These interactions are present 
in the majority of the frames of the MD trajectory. Arg46 is positioned in the middle of 
hMOG35-55; hence the HBs formed with the TCR may further anchor the peptide firmly 
on the space between the two receptors. In this context, residues such as Asn53 that does 
not interact with any of the residues in the HLA receptor forms hydrogen bonds with 
Gln29 and Thr75 of the TCR (Table 2). These interactions are also present for most of 
the simulation time. 
 
3.3.3 Conformation characteristics of mutated hMOG35-55(Ala41) and hMOG35-
55(Ala41,46) analogues  
 The conformational analysis of the hMOG35-55(Ala41) and hMOG35-55(Ala41,46) 
analogues, revealed that the conformational changes in the peptide are more evident in 
the two variations of hMOG35-55 compared to the hMOG35-55 epitope (Figure 3a, red 
and black). The mutation in positions 41 and 46 of the hMOG35-55, affects the 
conformations of the peptide in the trimolecular complex. The substitution of Arg with 
Ala in both cases leads to loss of interactions between the peptide and the two receptors 
(HLA, TCR). The mutations and the subsequent change in the interactions formed by 
the peptide may explain the greater fluctuations with respect to the initial conformation 
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of the RMS values in Figure 3a (red and blue) over time compared to the hMOG35-55 
epitope (Figure 3a, green). Moreover, the clustering analysis performed in the two 
variants of the hMOG35-55 epitope, showed that there is a dominant conformation for 
the peptides inside the trimolecular complex (approximately 72% of the simulation 
time) as presented in Figure 5. 
 The analysis of the hydrogen bond interactions between the two mutated 
analogues of hMOG35-55, showed a loss of interactions with the receptors mainly with 
TCR (Table 2). As expected the particular loss is centered on the positions with the 
mutated amino acids (positions 41 and 46). The replacement of Arg by Ala causes the 
loss of the HBs observed in hMOG35-55 (Tables 2), that could be attributed to the 
increased polarity of Arg due to the guanidino group that can create an extensive 
interaction pattern. On the other hand, Ala bears a less bulky group, as a side chain, 
with no potential for creating hydrogen bonds. This mutation may cause indivertibly, 
conformational changes in the positioning of the peptide inside the cavity of the two 
receptors. As presented in Figure 5 (red), the dominant conformation of the wt–
hMOG35-55 peptide is more bend when compared to the representative conformations 
adopted during the MD simulations by hMOG35-55(Ala41) (Figure 5, green) and 
hMOG35-55(Ala41,46) (Figure 5, yellow). The Arg in positions 41 and 46 are found on 
either side of a loop in the TCR binding site with polar residues such as Asp98, Ser101 
and Asn104. These polar residues interact with Arg in the hMOG35-55 epitope and assist 
to anchor the peptide in the TCR receptor. These interactions are not present on the 
hMOG35-55(Ala41) and hMOG35-55(Ala41,46) variants.  
 Additionally, a significant aspect observed in the three different MD simulations 
of the trimolecular complex (TCR-hMOG35-55-HLA DR2 receptor) is the retention of 
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the interactions of Phe at position 44 of the hMOG35-55 epitope. In both variants of 
hMOG35-55 and in the hMOG35-55, the particular residue forms hydrogen bonds with 
Gln70 in the HLA receptor (Table 1) that are present throughout the MD simulation. 
 
 
 
 
 
 
 
 
 
Figure 5: The dominant representative conformations of the hMOG35-55 (red) and the 
two variants hMOG35-55(Ala41) (green) and hMOG35-55(Ala41,46) (yellow) at the 
interface between the HLA receptor (top) and TCR (bottom). The residues at positions 
41 and 46 are presented as sticks while the rest of the proteins are presented as ribbon.  
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4. Discussion 
 The theoretical analysis based on the MD simulations, shows that hMOG35-55 can 
be an important activator of T-cells. The conformational analysis inside the HLA 
receptor and in the trimolecular complex revealed similar positioning with the MBP83-
96 peptide, suggesting a comparable mode of interaction between the two epitopes and 
the two receptors. In regard to the interactions between the epitopes and the HLA-DR2 
receptor, we observe that the residues involved in HBs have similar chemical properties 
(Figure 2). These similarities (hydrophobic nature, charged side chains) may provide 
valuable information regarding the type of interactions between the different epitopes 
and the receptor. Thus, it is possible to cluster the interactions of the epitopes in groups 
and identify common patterns. The comparison of these interactions between the 
hMOG35-55 epitope and the HLA are comparable to those of MBP83-96 (Figure 2), 
nevertheless these two antigens exhibit a sequence similarity of only 14%. This may be 
partially explained by the fact that the residues interacting with the receptor have similar 
side chains (Figure 2). 
 The majority of HBs between the hMOG35-55 epitope and the HLA DR2 receptor 
stems mainly from residues Trp39 and Arg41. The same Arg also presents a high number 
of interactions with the TCR, suggesting that the particular residue plays a critical role 
in antigen identification by T-cells. It can also be deduced that the approach of TCR 
towards the peptide/HLA DR2 receptor complex leads to the increase of the HBs inside 
the newly formed trimolecular complex. Subsequently, this might indicate that the 
antigen binding affinity is amplified once it is placed between the two receptors. 
 We concluded that key residues that enable the interactions between hMOG35-55 
and the TCR are Arg41 and Arg46. Arg at positions 41 and 46 of the peptide create an 
extensive HB network with both receptors. The substitution of Arg, at positions 41 and 
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46 of the epitope, with Ala leads to changes in the interactions of the peptide. Ala, in 
contrast to Arg, has a very small, non-polar side chain group that subsequently may 
affect the potential of the peptide to interact with TCR, since the particular position is 
solvent exposed and thus favours the presence of hydrophilic residues. As observed 
with the two variants of hMOG35-55 [hMOG35-55(Ala41) and hMOG35-55(Ala41,46)], the 
mutation of Arg to Ala leads to loss of interactions between the TCR and hMOG35-55 
(Table 2), while retaining the same pattern of HBs and binding affinity towards the 
HLA receptor (Table 1). In both the hMOG35-55 and its mutations, the interactions 
between Phe44 and the HLA receptor are identical in nature.  
 
5. Conclusion 
 The peptide variants [hMOG35-55(Ala41) and hMOG35-55(Ala41,46)] have proved 
to act as inhibitors of EAE, which is the animal model for MS.26 The information 
compiled during our studies confirms that the mutation of key residues in hMOG35-55 
leads to competitive binding to the HLA receptor and loss of key interactions with the 
TCR, thus preventing the formation of the trimolecular complex. This report provides 
a comprehensive theory regarding the interactions and conformational changes 
observed in the formation of the trimolecular complex (TCR-hMOG35-55-HLA DR2 
receptor) and highlights key interactions of the hMOG35-55 epitope. 
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